Development of a Therapeutic Endpoint in Pediatric Rheumatologic Conditions | MicrobiomeTrials← Back to trialsNCT04833465
Development of a Therapeutic Endpoint in Pediatric Rheumatologic Conditions
RecruitingOBSERVATIONAL
Trial Details
Start: 2021-07-16Est. Completion: 2028-04
Enrollment target: 90 participants Locations- Children's National Health System, Washington D.C., District of Columbia, United States
Other microbiome trials you might be interested in
Active Juvenile Psoriatic Arthritis
The study will aim to estimate the efficacy of apremilast compared with placebo in the treatment of juvenile psoriatic a…
Bregenz, AustriaEst. completion Mar 21, 2028
Idiopathic Inflammatory MyopathyDermatomyositisAnti-Synthetase SyndromeImmune-Mediated Necrotizing MyopathyJuvenile DermatomyositisJuvenile PolymyositisJuvenile Idiopathic Inflammatory Myopathy (JIIM)
Juvenile Myositis
RESET-Myositis: Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects with Active Idiopathic Infl…
Orange, United StatesEst. completion Jul 2028